ORAL DRUGS FOR PATHOGENETIC TREATMENT OF MULTIPLE SCLEROSIS
https://doi.org/10.21518/2079-701X-2017-11-40-43
Abstract
This article presents a review of the efficacy and safety of three oral drugs for multiple sclerosis, which are registered in the Russian Federation: teriflunomide, dimethylfumarate, fingolimod.
About the Authors
E. V. Popova
Russian National Research Medical University
Russian Federation
Russian Federation
A. N. Boyko
Russian National Research Medical University
Russian Federation
Russian Federation
E. I. Gusev
Russian National Research Medical University
Russian Federation
Russian Federation
References
1. Utz K, Hoog J, Wentrup A et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Therapeutic Advances in Neurological Disorders, 2014, 7(6): 263-275. doi:10.1177/1756285614555335.
2. Claussen MKorn T. Immune mechanisms of new therapeutic strategies in MS – Teriflunomide. Clinical Immunology, 2012, 142(1): 49-56. doi:10.1016/j.clim.2011.02.011.
3. Bar-Or A. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Experimental Neurology, 2014, 262: 57-65. doi:10.1016/j.expneurol.2014.06.005.
4. Garnock-Jones K. Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis. CNS Drugs, 2013, 27(12): 1103-1123. doi:10.1007/s40263-013-0118-2.
5. O’Connor P, Li D, Freedman M et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology, 2006, 66(6): 894-900. doi:10.1212/01.wnl.0000203121.04509.31.
6. Confavreux C, Li D, Freedman M et al. Longterm follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis Journal, 2012, 18(9): 1278-1289. doi:10.1177/1352458512436594.
7. O’Connor P, Wolinsky J, Confavreux C et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2011, 365(14): 1293-1303. doi:10.1056/nejmoa1014656.
8. Confavreux C, O’Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Neurology, 2014, 13(3): 247-256. doi:10.1016/s1474-4422(13)70308-9.
9. Vermersch P, Czlonkowska A, Grimaldi L et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2013, 20(6): 705-716. doi:10.1177/1352458513507821.
10. Comi G, Freedman M, Kappos L et al. Pooled safety and tolerability data from four placebocontrolled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 2016, 5: 97-104. doi:10.1016/j.msard.2015.11.006.
11. Sbergfeld НW. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine, 2009, 76(6): 361-367. doi:10.3949/ccjm.76a.08080.
12. Litjens N, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology, 2004, 58(4): 429-432. doi:10.1111/j.1365-2125.2004.02145.x.
13. Albrecht P, Bouchachia I, Goebels N et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation, 2012, 9(1): 163. doi:10.1186/1742-2094-9-163.
14. Zoghi S, Amirghofran Z, Nikseresht A, Ashjazadeh N, Kamali-Sarvestani E, Rezaei N. Cytokine Secretion Pattern in Treatment of Lymphocytes of Multiple Sclerosis Patients with Fumaric Acid Esters. Immunological Investigations, 2011, 40(6): 581-596. doi:10.3109/08820139.2011.569626.
15. Longbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, doi:10.1177/1352458515608961.
16. Gold R, Kappos L, Arnold D et al. PlaceboControlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012 367(12): 1098-1107. doi:10.1056/nejmoa1114287.
17. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol, 2006, 13(6): 604-610. doi:10.1111/j.1468-1331.2006.01292.x.
18. MacManus D, Miller D, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology, 2010, 258(3): 449-456. doi:10.1007/s00415-010-5777-z.
19. Fox R, Miller D, Phillips J et al. PlaceboControlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367(12): 1087-1097. doi:10.1056/nejmoa1206328.
20. O’Gorman J, Russell H, Li J, Phillips G, Kurukulasuriya N, Viglietta V. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. Clinical Therapeutics, 2015, 37(7): 1402-1419.e5. doi:10.1016/j.clinthera.2015.03.028.
21. Berkovich R, Weiner L. Effects of dimethyl fumarate on lymphocyte subsets. Multiple Sclerosis and Related Disorders, 2015, 4(4): 339-341. doi:10.1016/j.msard.2015.06.002.
22. Cohen J, Barkhof F, Comi G et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362(5): 402-415. doi:10.1056/nejmoa0907839.
23. Kappos L, Radue E, O’Connor P et al. A PlaceboControlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362(5): 387-401. doi:10.1056/nejmoa0909494.
24. Попова Е.В., Ялымов А.А., Бойко А.Н., Давыдовская М.В., Кольяк Е.В., Трактирская О.В., Хачанова Н.В., Щур С.Г. Финголимод в лечении ремиттирующего рассеянного склероза: опыт применения в московском городском центре рассеянного склероза. Медицинский совет, 2014, 5: 60-62.
Review
For citations:
Popova EV, Boyko AN, Gusev EI. ORAL DRUGS FOR PATHOGENETIC TREATMENT OF MULTIPLE SCLEROSIS. Meditsinskiy sovet = Medical Council. 2017;(11):40-43. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-40-43
Views:
948
Email this article 